For instance, in the context of melanoma, IFI30 has been demonstrated to potentiate the processing and presentation of tumour antigens, TRP1 and TRP2, consequentially augmenting anti-tumour T cell responses and culminating in enhanced patient survival rates (16–18). Here, IFI30 is linked to neoplasm.